<u>MHRA approves vibegron to treat adult</u> <u>patients with Overactive Bladder</u> <u>Syndrome (OAB)</u>

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 17 July 2024, approved the medicine vibegron (Obgemsa) to treat the symptoms of overactive bladder (OAB) syndrome in adults. Symptoms may include a ...